ArticleAdvances in therapy2022

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.

Markus Cornberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.